The 340B drug pricing program started as a narrow safety-net mechanism and has evolved into one of the most contested — and commercially significant — elements of the US drug pricing system. For manufacturers in oncology, specialty, and hospital-administered categories, 340B is a material revenue impact. Understanding the program’s mechanics, and where it’s heading legally and politically, is not optional for brand teams in affected categories.
What 340B Actually Is
Section 340B of the Public Health Service Act requires drug manufacturers participating in Medicaid to sell outpatient drugs at significantly discounted prices — typically 20-50% below average manufacturer price — to covered entities. Covered entities include federally qualified health centers, Ryan White HIV/AIDS clinics, children’s hospitals, and disproportionate share hospitals serving low-income populations.
The program’s original intent was to allow safety-net providers to stretch scarce resources further for underserved patients. The economic model was simple: covered entities purchase drugs at 340B prices, dispense them to patients reimbursed at commercial or Medicaid rates, and keep the spread to fund operations. That spread — the 340B “profit” — is substantial in high-priced specialty categories and is now a significant revenue line for many large health systems that qualify as covered entities.
The Contract Pharmacy Problem
The program’s expansion has been driven largely by contract pharmacy arrangements. Covered entities are permitted to use outside pharmacies — including national chains — to dispense 340B drugs on their behalf. This dramatically expanded the number of pharmacies dispensing 340B drugs and the volume of drugs covered by the discount requirement.
Manufacturers including AstraZeneca, Eli Lilly, Novartis, and Bristol Myers Squibb have attempted to restrict 340B discounts to drugs dispensed at a single in-house pharmacy, arguing that contract pharmacy arrangements go beyond the statutory intent of the program. HRSA and courts have largely sided against manufacturers in these disputes, though the legal landscape continues to evolve. The result: contract pharmacy remains a primary vector for 340B volume growth in categories where manufacturers have unsuccessfully contested it.
The Revenue Impact by Category
340B’s impact is not evenly distributed. Oncology is the most affected therapeutic area because: cancer drugs are expensive, oncology is administered predominantly in hospital outpatient settings, and large academic medical centers — which qualify as covered entities — are often the highest-volume prescribers. Specialty categories administered by infusion (biologics, immunology) are similarly affected. Primary care oral brands with predominantly retail distribution have minimal 340B exposure.
For a brand with significant hospital outpatient volume in an oncology indication, 340B discounts can reduce realized net revenue by 10-20% on affected units — on top of standard commercial rebates, Medicaid best price obligations, and government program pricing. Teams that model launch economics without a 340B channel assumption are building on incomplete foundations.
Where the Program Is Heading
Congressional and administrative pressure on 340B reform has intensified, with debates about whether the program’s benefits are reaching patients or accruing to health system margins. HRSA’s pilot programs exploring rebate-based models represent a potential structural shift — moving from an upfront discount to a retrospective rebate conditioned on patient eligibility — but implementation has been contested by hospital groups.
The commercial planning implication: 340B is unlikely to contract significantly in the near term, but its operating rules are in flux. Manufacturers with large 340B exposure should be modeling scenarios for rebate-based conversion, contract pharmacy restrictions, and covered entity eligibility tightening — and maintaining active engagement with HRSA and Congressional offices rather than treating this as background noise.
Related coverage: Drug Pricing & Market Access Hub.
